Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Central European Leukemia Study Group.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Central European Leukemia Study Group
ClinicalTrials.gov Identifier:
NCT00327262
First received: May 16, 2006
Last updated: June 16, 2006
Last verified: September 2005